KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to $111.5 million.

  • Alnylam Pharmaceuticals' Net Income towards Common Stockholders rose 23316.5% to $111.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $278.1 million, marking a year-over-year increase of 19997.91%. This contributed to the annual value of $313.7 million for FY2025, which is 21279.49% up from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' Net Income towards Common Stockholders stood at $111.5 million, which was up 23316.5% from $251.1 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $251.1 million for Q3 2025, and its period low was -$405.9 million during Q3 2022.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$156.0 million (2023), whereas its average is -$121.2 million.
  • Within the past 5 years, the most significant YoY rise in Alnylam Pharmaceuticals' Net Income towards Common Stockholders was 32504.62% (2025), while the steepest drop was 29242.7% (2025).
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Net Income towards Common Stockholders stood at -$258.5 million in 2021, then rose by 19.72% to -$207.5 million in 2022, then skyrocketed by 33.55% to -$137.9 million in 2023, then skyrocketed by 39.24% to -$83.8 million in 2024, then surged by 233.17% to $111.5 million in 2025.
  • Its Net Income towards Common Stockholders was $111.5 million in Q4 2025, compared to $251.1 million in Q3 2025 and -$66.3 million in Q2 2025.